Adverum Biotechnologies announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023. Dr. Nicholson brings over forty years of pharmaceutical experience, a proven track record in drug development, and deep experience in ophthalmology, most recently as chief research and development officer at Allergan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADVM:
- ADVM Upcoming Earnings Report: What to Expect?
- Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
- Adverum announces 3-year efficacy, safety results from OPTIC extension study
- Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
- Adverum Biotechnologies initiated with a Buy at Mizuho
